Newfeed

NEW YORK, Jan. 22, 2024 /PRNewswire/ — The intracranial pressure monitoring devices market size is estimated to grow by USD 568.32 million from 2023 to 2027 at a CAGR of 6.5% according to Technavio. The market share growth by the invasive segment will be significant during the forecast perio

AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bausch Health Co Inc., Bayer AG, Bristol Myers Squibb Co., Clovis Oncology, Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., LG Chem Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Ta

Magazine made for you.

Featured:

No posts were found for provided query parameters.

Elsewhere: